79332232 - HUMABODY

Information

• Trademark
• 79332232

• Source

• Serial Number

  79332232

• Registration Number

  7064382

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 40 - Treatment of materials
  • 42 - Scientific and technological services and research and design relating thereto
  • 45 - Legal services

• Filing Date

  August 12, 2021
  4 years ago

• Registration Date

  May 30, 2023
  2 years ago

• Transaction Date

  June 22, 2025
  3 months ago

• Status Date

  May 30, 2023
  2 years ago

• Published for Opposition Date

  March 14, 2023
  2 years ago

• Location Date

  May 30, 2023
  2 years ago

• Status Code

  700

• Current Location

  PUBLICATION AND ISSUE SECTION

  Employee Name

  RILEY, KATHERINE

• Attorney Docket Number

  315971USm0

  Attorney Name

  Matthew L. Frisbee

  Law Office Assigned Location Code

  M80

• Owners

  • CRESCENDO BIOLOGICS LTD

Case File Statements

• GS0401: Custom manufacture of chemicals, biologicals, antibodies and antibody fragments; services for the custom manufacture of therapies using antibodies and antibody fragments; custom manufacture of antibody and antibody fragments, for others, for use in medical therapies, including in relation to oncology; consultancy, advice and information relating to all of the aforesaid services
• DM0000: The mark consists of the wording "HUMABODY" in a stylized font.
• GS0051: Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; veterinary preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; therapeutic pharmaceutical preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodies, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; therapeutic preparations that use monoclonal antibodies, namely therapeutic pharmaceutical for treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for medical and veterinary diagnostics; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases for use in the discovery, preclinical and clinical development of therapeutic products for medical and veterinary purposes; pharmaceutical preparations for use in oncology; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases for use in oncology and therapeutic treatments in relation thereto
• GS0451: Licensing of intellectual property, namely, licensing of research and development; licensing of intellectual property, namely, licensing of medical therapeutic research; licensing of intellectual property, namely, licensing of research relating to antibodies and antibody fragments; licensing of intellectual property, namely, licensing of research in relation to the formation, manufacture, medical usage and manipulation of antibodies and antibody fragments; consultancy, advice and information relating to all of the aforesaid services
• GS0011: Chemicals used in industry and science; Chemicals for use in science and industry, namely, chemicals for laboratory research purposes; chemicals for use in science and industry, namely, chemicals for use in medical research; chemicals for use in science and industry, namely, chemicals for use in oncological research; antibodies and antibody fragments for scientific and laboratory use in the nature of biochemicals, namely, monoclonal antibodies and antibody fragments for scientific and laboratory use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; laboratory chemicals, namely, antibody reagents used in cell and tissue assays for scientific and laboratory use; biochemicals, namely, monoclonal antibodies and antibody fragments for use in medical research; biochemicals, namely, monoclonal antibodies and antibody fragments for use in oncological research; molecules primarily comprised of antibodies and antibody fragments for use in medical research; molecules primarily comprised of antibodies and antibody fragments in the nature of biochemicals, namely, monoclonal antibodies and antibody fragments for use in oncological research; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical development, clinical development and manufacture of therapeutic products
• GS0421: Scientific and technological services, namely, research and design in the field of chemicals, biologicals, antibodies and antibody fragments; scientific laboratory research services relating to the development of antibodies and antibody fragments; oncological research; research into the development of antibodies and antibody fragments; scientific and technological services, namely, provision of antibodies and antibody fragments for medical and veterinary research and development in the field of chemicals, biologicals, antibodies and antibody fragments; engineering of antibodies and antibody fragments; scientific services, namely, discovery, preclinical and clinical development of therapeutic products; scientific research for others in the field of drug discovery, preclinical and clinical development of therapeutic and diagnostic products; research into antibodies, antibody fragments for others; research into the formation, manufacture, medical usage and manipulation of antibodies and antibody fragments for others; consultancy, advice and information relating to all of the aforesaid services

Case File Event Statements

• 2/8/2022 - 3 years ago

  3 - APPLICATION FILING RECEIPT MAILED Type: MAFR

• 2/3/2022 - 3 years ago

  1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR

• 2/4/2022 - 3 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 5/13/2022 - 3 years ago

  4 - ASSIGNED TO EXAMINER Type: DOCK

• 5/23/2022 - 3 years ago

  5 - NON-FINAL ACTION WRITTEN Type: CNRT

• 5/24/2022 - 3 years ago

  6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR

• 6/16/2022 - 3 years ago

  7 - REFUSAL PROCESSED BY MPU Type: RFRR

• 6/16/2022 - 3 years ago

  8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS

• 7/10/2022 - 3 years ago

  9 - CORRECTION TRANSACTION RECEIVED FROM IB Type: CRCV

• 7/13/2022 - 3 years ago

  10 - REFUSAL PROCESSED BY IB Type: RFNT

• 10/14/2022 - 3 years ago

  11 - CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED Type: CREV

• 10/28/2022 - 2 years ago

  12 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 10/28/2022 - 2 years ago

  13 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 10/28/2022 - 2 years ago

  14 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 11/15/2022 - 2 years ago

  15 - TEAS VOLUNTARY AMENDMENT RECEIVED Type: PARI

• 2/3/2023 - 2 years ago

  20 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 11/15/2022 - 2 years ago

  16 - PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED Type: AMPX

• 12/16/2022 - 2 years ago

  17 - FINAL REFUSAL WRITTEN Type: CNFR

• 12/16/2022 - 2 years ago

  18 - FINAL REFUSAL E-MAILED Type: GNFR

• 12/16/2022 - 2 years ago

  19 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN

• 2/3/2023 - 2 years ago

  21 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 2/3/2023 - 2 years ago

  22 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 2/3/2023 - 2 years ago

  23 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 2/6/2023 - 2 years ago

  24 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 2/22/2023 - 2 years ago

  25 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 3/14/2023 - 2 years ago

  29 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 5/30/2023 - 2 years ago

  32 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC

• 8/19/2023 - 2 years ago

  33 - RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED Type: RHRD

• 8/31/2023 - 2 years ago

  36 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS

• 2/22/2023 - 2 years ago

  26 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R

• 2/22/2023 - 2 years ago

  27 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS

• 3/14/2023 - 2 years ago

  28 - PUBLISHED FOR OPPOSITION Type: PUBO

• 3/15/2023 - 2 years ago

  30 - NOTIFICATION PROCESSED BY IB Type: GPNX

• 5/30/2023 - 2 years ago

  31 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 8/30/2023 - 2 years ago

  34 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR

• 11/8/2024 - 11 months ago

  39 - RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED Type: RHRD

• 6/3/2025 - 4 months ago

  40 - LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED Type: LIMN

• 6/17/2025 - 4 months ago

  43 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA

• 6/17/2025 - 4 months ago

  41 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP

• 6/17/2025 - 4 months ago

  42 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA

• 10/27/2023 - a year ago

  38 - LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED Type: LIMN

• 8/31/2023 - 2 years ago

  35 - FINAL DISPOSITION PROCESSED Type: FIMP

• 9/25/2023 - 2 years ago

  37 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO